Summary
Boston Scientific Corporation (BSX) filed an 8-K on October 23, 2019, primarily to furnish a press release announcing their financial results for the third quarter ended September 30, 2019. While the 8-K itself does not contain the detailed financial figures, it directs investors to the accompanying press release (Exhibit 99.1) for this crucial information. Investors should review the press release furnished with this filing for a comprehensive understanding of BSX's Q3 2019 performance. This includes key financial metrics such as revenue, earnings per share, and any forward-looking guidance provided by the company. It is important to note that the information presented in this 8-K, and its accompanying exhibit, is not deemed "filed" for purposes of Section 18 of the Exchange Act, meaning it does not carry the same legal liability as formally filed financial statements.
Key Highlights
- 1BSX filed an 8-K on October 23, 2019, to report on its Q3 2019 financial results.
- 2The core of the filing is the furnishing of a press release (Exhibit 99.1) with detailed Q3 earnings information.
- 3Investors need to consult Exhibit 99.1 for specific financial performance data for the quarter ended September 30, 2019.
- 4The filing does not contain detailed financial statements directly within the 8-K document itself.
- 5Information furnished under Item 2.02 is typically for informational purposes and is not considered 'filed' for liability under Section 18 of the Exchange Act.